0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Controversies |

New Therapy for Central Retinal Vein Occlusion:  Are Intravitreal Steroids a Possible Answer?

Mark S. Blumenkranz, MD
Arch Ophthalmol. 2005;123(2):259-261. doi:10.1001/archopht.123.2.259.
Text Size: A A A
Published online

Extract

The recent emphasis on new pharmacologic treatments for exudative age-related macular degeneration and diabetic retinopathy, while commendable, has tended to obscure the fact that another common retinal disorder, central retinal vein occlusion, is, for the most part, untreatable with significant visual morbidity. Based on a recent population-based survey of retinal venous occlusive disease in adults1 and US census figures for 2000,2 as many as 36 500 persons per year develop central retinal vein occlusion in the United States alone. Coupled with as many as 95 000 persons per year who develop branch retinal vein occlusion, the 2 entities combined may account for significant vision loss in more than 130 000 persons per year in the United States. This begins to approach the annual incidence of cases of exudative age-related macular degeneration and makes it increasingly apparent from a public health standpoint that new and effective therapies are desperately needed.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 5

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();